Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PM10 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PM10 | DRUG | - |
Inclusion Criteria: * Be a healthy male or female 18 to 55 years of age, inclusive. Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial and must have a negative serum pregnancy test at screening and upon check-in to the study faci...
PM10 is a small molecule drug candidate developed by Baxter International Inc. under the ticker BAX. It has been studied in Phase 1 clinical development. Baxter has not publicly disclosed the specific indications or therapeutic area PM10 is being developed to treat.
PM10 is being developed by Baxter International Inc., which trades on the New York Stock Exchange under the ticker BAX. Baxter is the sponsor of the clinical program for this small molecule candidate.
PM10 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The program has completed one Phase 1 trial, and no active trials are currently listed.
PM10 has been studied in one completed Phase 1 trial, NCT00502346, titled a trial to determine the relative effect of PM101 I.V. versus placebo on hemodynamics in healthy adult volunteers. The trial enrolled 342 healthy volunteers in Canada and was randomized and double blind.
PM10 and PM101 refer to the same Baxter International Inc. drug candidate. The completed Phase 1 trial NCT00502346 was registered under the name PM101, while the asset is also referred to as PM10. Both names describe the same small molecule program.